2 research outputs found
Hypoxia-Directed and Self-Immolative Theranostic Agent: Imaging and Treatment of Cancer and Bacterial Infections
The impact of bacteria on cancer progression and treatment
is becoming
increasingly recognized. Cancer-associated bacteria are linked to
metastases, reduced efficacy, and survival challenges. In this study,
we present a sensitive hypoxia-activated prodrug, NR-NO2, which comprises an antibiotic combined
with a chemotherapeutic. This prodrug demonstrates rapid and robust
fluorescence enhancement and exhibits potent antibacterial activity
against both Gram-positive and Gram-negative bacteria as well as tumor
cells. Upon activation, NR-NO2 produces a distinct “fluorescence-on” signal, enabling
real-time drug release monitoring. By leveraging elevated nitroreductase
in cancer cells, NR-NO2 gives
rise to heightened bacterial cytotoxicity while sparing normal cells.
In A549 solid tumor-bearing mice, NR-NO2 selectively accumulated at tumor sites, displaying fluorescence
signals under hypoxia superior to those of a corresponding prodrug-like
control. These findings highlight the potential of NR-NO2 as a promising cancer therapy prodrug that
benefits from targeted release, antibacterial impact, and imaging-based
guidance
Hypoxia-Directed and Self-Immolative Theranostic Agent: Imaging and Treatment of Cancer and Bacterial Infections
The impact of bacteria on cancer progression and treatment
is becoming
increasingly recognized. Cancer-associated bacteria are linked to
metastases, reduced efficacy, and survival challenges. In this study,
we present a sensitive hypoxia-activated prodrug, NR-NO2, which comprises an antibiotic combined
with a chemotherapeutic. This prodrug demonstrates rapid and robust
fluorescence enhancement and exhibits potent antibacterial activity
against both Gram-positive and Gram-negative bacteria as well as tumor
cells. Upon activation, NR-NO2 produces a distinct “fluorescence-on” signal, enabling
real-time drug release monitoring. By leveraging elevated nitroreductase
in cancer cells, NR-NO2 gives
rise to heightened bacterial cytotoxicity while sparing normal cells.
In A549 solid tumor-bearing mice, NR-NO2 selectively accumulated at tumor sites, displaying fluorescence
signals under hypoxia superior to those of a corresponding prodrug-like
control. These findings highlight the potential of NR-NO2 as a promising cancer therapy prodrug that
benefits from targeted release, antibacterial impact, and imaging-based
guidance